European Medicines Agency's Management Board Nominates Guido Rasi as New Executive Director
The European Medicines Agency's Management Board has nominated Guido Rasi on June 8,2011 as new Executive Director of the Agency. The Executive Director-designate has been invited to a hearing in front of the European Parliament Committee on Environment, Public Health and Food Safety on July 13, 2011. The Board will officially appoint the new Executive Director following his hearing and a positive response from the European Parliament.
Mr. Rasi has been Director-General of the Italian Medicines Agency since 2008, and member of the European Medicines Agency's Management Board since 2010.
Mr. Rasi holds a degree in medicine and surgery, with specialization in internal medicine, allergology, and clinical immunology from the University of Rome. From 1978 to 1990, Mr. Rasi worked as physician in hospital, research, and private practice. He worked from 1990 to 2008 in research at the Institute for Experimental Medicine of the National Research Council in Rome, directing the molecular medicine section from 2002 to 2005 and the Tor Vegata section from 2005 to 2008. He was made full professor of microbiology at the University of Rome (Tor Vegata) in 2008.
Andreas Pott will continue his role as Acting Executive Director until Guido Rasi takes office.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
